Compare BDN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDN | AUTL |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.7M | 532.3M |
| IPO Year | 1995 | 2025 |
| Metric | BDN | AUTL |
|---|---|---|
| Price | $3.28 | $2.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.50 | ★ $8.50 |
| AVG Volume (30 Days) | 2.0M | ★ 3.2M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.67% | N/A |
| EPS Growth | ★ 9.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $484,454,000.00 | $10,120,000.00 |
| Revenue This Year | $12.96 | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $2.47 | $1.18 |
| 52 Week High | $4.63 | $2.58 |
| Indicator | BDN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 64.81 |
| Support Level | $2.90 | $1.32 |
| Resistance Level | $3.31 | $2.43 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 74.24 | 73.32 |
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.